To compare the effects of two antihypertensive drugs amlodipine and cilnidipine in mild to moderate hypertention

A Prospective Randomized Comparison of Clinical and Biochemical Effects of Amlodipine and Cilnidipine in Newly Diagnosed Cases of Mild to Moderate Hypertension - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064192

Enrollment

Registered

2024-03-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Cilnidipine: Group B : Cilnidipine 10 mg once daily for 3 months Control Intervention1: Amlodipine: Group A : Amlodipine 5 mg once daily for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed Mild to Moderate Hypertensive patients 2. Patients of either sex between 18 years to 60 years

Exclusion criteria

Exclusion criteria: 1. Patients above 60 years of age 2. History of severe hepatic, renal disease, and severe cardiac disease 3. Pregnant and lactating mothers 4. Major Depressive Disorder with Psychotic symptoms 5. PATIENTS ON DRUGS WITH KNOWN INTERVENTIONS WITH THE STUDY OF DRUGS

Design outcomes

Primary

Measure	Time frame
To study the effect of Amlodipine and Cilnidpine on Systolic and Diastolic Blood Pressure In Patients of HypertensionTimepoint: Baseline, Week 4, Week 8 and Week 12	—

Secondary

Measure	Time frame
To compare safety & tolerability of two study groupsTimepoint: Baseline, Week 4, Week 8 & Week 12;To compare the effect of the two drugs on renal parametersTimepoint: Baseline, Week 4, Week 8 & Week 12	—

Countries

India

Contacts

Public ContactLajvir Singh

Government Medical College, Amritsar

inderpalpharma@gmail.com9815550138

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026